Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00769275 · ClinicalTrials.gov registry record

Detection of Ischemia in Asymptomatic Diabetics

A clinical trial of Type 2 Diabetes Mellitus, sponsored by Yale University.

Completed
Registry status
1,123
Enrollment target
1
Study location

NCT00769275 is a study of Type 2 Diabetes Mellitus that has completed, run by Yale University. The registered enrollment target is 1,123 participants, below the 2,739-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00769275, a study of Type 2 Diabetes Mellitus, has completed, sponsored by Yale University.

COMPLETED
Registry status
1,123 participants
Enrollment target
1
Study location

Study Summary

Asymptomatic subjects with Type 2 Diabetes Mellitus were randomized to either screening with Tc-99m sestamibi adenosine SPECT imaging or no screening. All patients will be followed for 5 years for the occurrence of cardiac death or non-fatal myocardial infarction. The aims are: 1. To prospectively assess the prevalence of silent myocardial ischemia in asymptomatic subjects with Type 2 Diabetes Mellitus. 2. To identify on the basis of clinical and/or biochemical variables in a high-risk cohort in which screening for coronary artery disease is appropriate. 3. To assess progression of (silent) myocardial ischemia after 3 years. 4. To assess the occurence of cardiac death or nonfatal myocardial infarction during 5 years follow-up in screened and not screened subjects.

Conditions Studied

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 1,123 participants
Start Date 2000-08
Est. Completion 2008-01

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT00769275

The ClinicalTrials.gov registry entry for NCT00769275 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,739-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (59% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.

NCT00769275 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00769275 about?

NCT00769275 is a clinical study titled "Detection of Ischemia in Asymptomatic Diabetics". Asymptomatic subjects with Type 2 Diabetes Mellitus were randomized to either screening with Tc-99m sestamibi adenosine SPECT imaging or no screening. All patients will be followed for 5 years for the occurrence of cardiac death or non-fatal myocardial infarction. The aims are: 1. To prospectively...

What is the current status of trial NCT00769275?

This trial is currently completed. The enrollment target is 1,123 participants. The study started on 2000-08. Estimated completion is 2008-01.

What conditions does trial NCT00769275 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

Who is sponsoring clinical trial NCT00769275?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00769275 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.